Terug

Watch Compare

Medicus Pharma Ltd.

Datakwaliteit: 83%

Ook genoteerd als MDCXW Nasdaq

MDCX

Nasdaq Manufacturing Chemicals

€ 0,45

▼ € 0,02 (-4,07%)

Marktkapitalisatie: 17,61 M

Prijs

€ 0,45

Marktkapitalisatie

17,61 M

Dagbereik

€ 0,44 — € 0,47

52-Weeksbereik

€ 0,37 — € 8,94

Volume

734.224

Openen € 0,47

50D / 200D Gem.

€ 0,89

49,61% below

50D / 200D Gem.

€ 1,92

76,71% below

Quick Summary

Belangrijkste Punten

Negative free cash flow of -22,78 M

Groei

Revenue Growth (5Y)

N/A

Revenue (1Y)N/A

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Kwaliteit

Return on Equity

-4043,60%

Onder sectorgemiddelde (-53,41%)

ROIC-2003,07%

Net MarginN/A

Op. MarginN/A

Veiligheid

Debt / Equity

N/A

Current Ratio0,92

Interest Coverage-174,08

Waardering

PE (TTM)

-0,37

Boven sectorgemiddelde (-1,48)

P/B RatioN/A

EV/EBITDAN/A

Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)

Metriek	Aandeel	Sector Mediaan
P/E	-0,4	-1,5
P/B	—	1,6
ROE %	-4043,6	-53,4
Net Margin %	—	-41,5
Rev Growth 5Y %	—	1,8
D/E	—	0,3

All Fundamental Metrics

Growth
Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	N/A	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	N/A	Net Income (TTM)	-47,28 M
ROE	-4043,60%	ROA	-431,55%
Gross Margin	N/A	Operating Margin	N/A
Net Margin	N/A	Free Cash Flow (TTM)	-22,78 M
ROIC	-2003,07%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	N/A	Current Ratio	0,92
Interest Coverage	-174,08	Asset Turnover	N/A
Working Capital	-876.489	Tangible Book Value	-910.126
Dividends
Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	-0,37	Forward P/E	N/A
P/B Ratio	N/A	P/S Ratio	N/A
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	N/A	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	-129,36%
Market Cap	17,61 M	Enterprise Value	8,94 M
Per Share
EPS (Diluted TTM)	-2,74	Revenue / Share	N/A
FCF / Share	-0,58	OCF / Share	-0,58
EPS CAGR (1Y)	N/A	EPS CAGR (5Y)	N/A
EPS CAGR (10Y)	N/A
Efficiency
CapEx / Revenue	N/A	FCF Conversion	48,17%
SBC-Adj. FCF	-24,29 M	Growth Momentum	N/A

Income Statement

Annual, most recent first

Metric	FY2025	FY2024
Revenue	—	—
Net Income	-47,28 M	-11,16 M
EPS (Diluted)	-2,74	-1,16
Gross Profit	—	—
Operating Income	-34,36 M	-11,18 M
EBITDA	—	—
R&D Expenses	7,72 M	3,53 M
SG&A Expenses	—	—
D&A	—	—
Interest Expense	-197.382,0	—
Income Tax	0,0	0,0

Balance Sheet

Annual, most recent first

Metric	FY2025	FY2024
Total Assets	10,06 M	5,65 M
Total Liabilities	10,02 M	2,51 M
Shareholders' Equity	-67.554,0	3,13 M
Total Debt	—	—
Cash & Equivalents	8,71 M	4,16 M
Current Assets	9,89 M	5,38 M
Current Liabilities	9,94 M	2,31 M